- Home
- GEG vs FLNA Comparison
GEG vs FLNA Comparison
Compare GEG & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEG | FLNA |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.4M | 61.8M |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | GEG | FLNA |
|---|---|---|
| Price | $2.24 | $0.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.7K | ★ 252.3K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,974,000.00 | $41,119,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.70 | N/A |
| 52 Week Low | $1.80 | $0.85 |
| 52 Week High | $3.14 | $2.03 |
Technical Indicators
Market Signals| Indicator | GEG | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 36.47 |
| Support Level | $2.09 | $0.85 |
| Resistance Level | $2.20 | $0.99 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 38.89 | 6.45 |
Price Performance
Historical ComparisonAbout GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.